Linking cognitive functioning to multimodal imaging in multiple sclerosis (MS)

Brief description of study

The purpose of this study is to link cognitive function in multiple sclerosis (MS) with changes in the brain related to MS and to see the effects of a disease modifying therapy (Tecfidera, Tysabri or Ocrevus) for preserving cognitive function. In particular, cognitive assessments and PET/MRI scans for MS participants on Tecfidera will be compared to healthy controls.Tecfidera (dimethyl fumarate), Tysabri and Ocrevus are approved by the US Food and Drug Administration (FDA) for use in patients with RRMS. In this study, you will receive Tecfidera, Tysabri or Ocrevus as part of your Standard of Care (you would receive this treatment whether or not you participated in this study) and we will look at your cognitive function and brain pathophysiology through the course of treatment.


Clinical Study Identifier: s17-00238
ClinicalTrials.gov Identifier: NCT03723356


If you are registered as a volunteer, please login to the dashboard to send referrals.